Antibody-drug Conjugate for Cancer and Forecast Market
1 Introduction to Research & Analysis Reports
1.1 Antibody-drug Conjugate for Cancer Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Antibody-drug Conjugate for Cancer Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Antibody-drug Conjugate for Cancer Overall Market Size
2.1 Global Antibody-drug Conjugate for Cancer Market Size: 2021 VS 2028
2.2 Global Antibody-drug Conjugate for Cancer Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Antibody-drug Conjugate for Cancer Players in Global Market
3.2 Top Global Antibody-drug Conjugate for Cancer Companies Ranked by Revenue
3.3 Global Antibody-drug Conjugate for Cancer Revenue by Companies
3.4 Top 3 and Top 5 Antibody-drug Conjugate for Cancer Companies in Global Market, by Revenue in 2021
3.5 Global Companies Antibody-drug Conjugate for Cancer Product Type
3.6 Tier 1, Tier 2 and Tier 3 Antibody-drug Conjugate for Cancer Players in Global Market
3.6.1 List of Global Tier 1 Antibody-drug Conjugate for Cancer Companies
3.6.2 List of Global Tier 2 and Tier 3 Antibody-drug Conjugate for Cancer Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Antibody-drug Conjugate for Cancer Market Size Markets, 2021 & 2028
4.1.2 Hematological Malignancies Drugs
4.1.3 Solid Tumor Drugs
4.2 By Type - Global Antibody-drug Conjugate for Cancer Revenue & Forecasts
4.2.1 By Type - Global Antibody-drug Conjugate for Cancer Revenue, 2017-2022
4.2.2 By Type - Global Antibody-drug Conjugate for Cancer Revenue, 2023-2028
4.2.3 By Type - Global Antibody-drug Conjugate for Cancer Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Antibody-drug Conjugate for Cancer Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Pharmacy
5.1.4 Other
5.2 By Application - Global Antibody-drug Conjugate for Cancer Revenue & Forecasts
5.2.1 By Application - Global Antibody-drug Conjugate for Cancer Revenue, 2017-2022
5.2.2 By Application - Global Antibody-drug Conjugate for Cancer Revenue, 2023-2028
5.2.3 By Application - Global Antibody-drug Conjugate for Cancer Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Antibody-drug Conjugate for Cancer Market Size, 2021 & 2028
6.2 By Region - Global Antibody-drug Conjugate for Cancer Revenue & Forecasts
6.2.1 By Region - Global Antibody-drug Conjugate for Cancer Revenue, 2017-2022
6.2.2 By Region - Global Antibody-drug Conjugate for Cancer Revenue, 2023-2028
6.2.3 By Region - Global Antibody-drug Conjugate for Cancer Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Antibody-drug Conjugate for Cancer Revenue, 2017-2028
6.3.2 US Antibody-drug Conjugate for Cancer Market Size, 2017-2028
6.3.3 Canada Antibody-drug Conjugate for Cancer Market Size, 2017-2028
6.3.4 Mexico Antibody-drug Conjugate for Cancer Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Antibody-drug Conjugate for Cancer Revenue, 2017-2028
6.4.2 Germany Antibody-drug Conjugate for Cancer Market Size, 2017-2028
6.4.3 France Antibody-drug Conjugate for Cancer Market Size, 2017-2028
6.4.4 U.K. Antibody-drug Conjugate for Cancer Market Size, 2017-2028
6.4.5 Italy Antibody-drug Conjugate for Cancer Market Size, 2017-2028
6.4.6 Russia Antibody-drug Conjugate for Cancer Market Size, 2017-2028
6.4.7 Nordic Countries Antibody-drug Conjugate for Cancer Market Size, 2017-2028
6.4.8 Benelux Antibody-drug Conjugate for Cancer Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Antibody-drug Conjugate for Cancer Revenue, 2017-2028
6.5.2 China Antibody-drug Conjugate for Cancer Market Size, 2017-2028
6.5.3 Japan Antibody-drug Conjugate for Cancer Market Size, 2017-2028
6.5.4 South Korea Antibody-drug Conjugate for Cancer Market Size, 2017-2028
6.5.5 Southeast Asia Antibody-drug Conjugate for Cancer Market Size, 2017-2028
6.5.6 India Antibody-drug Conjugate for Cancer Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Antibody-drug Conjugate for Cancer Revenue, 2017-2028
6.6.2 Brazil Antibody-drug Conjugate for Cancer Market Size, 2017-2028
6.6.3 Argentina Antibody-drug Conjugate for Cancer Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Antibody-drug Conjugate for Cancer Revenue, 2017-2028
6.7.2 Turkey Antibody-drug Conjugate for Cancer Market Size, 2017-2028
6.7.3 Israel Antibody-drug Conjugate for Cancer Market Size, 2017-2028
6.7.4 Saudi Arabia Antibody-drug Conjugate for Cancer Market Size, 2017-2028
6.7.5 UAE Antibody-drug Conjugate for Cancer Market Size, 2017-2028
7 Players Profiles
7.1 Gilead Sciences
7.1.1 Gilead Sciences Corporate Summary
7.1.2 Gilead Sciences Business Overview
7.1.3 Gilead Sciences Antibody-drug Conjugate for Cancer Major Product Offerings
7.1.4 Gilead Sciences Antibody-drug Conjugate for Cancer Revenue in Global Market (2017-2022)
7.1.5 Gilead Sciences Key News
7.2 Roche
7.2.1 Roche Corporate Summary
7.2.2 Roche Business Overview
7.2.3 Roche Antibody-drug Conjugate for Cancer Major Product Offerings
7.2.4 Roche Antibody-drug Conjugate for Cancer Revenue in Global Market (2017-2022)
7.2.5 Roche Key News
7.3 Pfizer
7.3.1 Pfizer Corporate Summary
7.3.2 Pfizer Business Overview
7.3.3 Pfizer Antibody-drug Conjugate for Cancer Major Product Offerings
7.3.4 Pfizer Antibody-drug Conjugate for Cancer Revenue in Global Market (2017-2022)
7.3.5 Pfizer Key News
7.4 Takeda
7.4.1 Takeda Corporate Summary
7.4.2 Takeda Business Overview
7.4.3 Takeda Antibody-drug Conjugate for Cancer Major Product Offerings
7.4.4 Takeda Antibody-drug Conjugate for Cancer Revenue in Global Market (2017-2022)
7.4.5 Takeda Key News
7.5 Seagen
7.5.1 Seagen Corporate Summary
7.5.2 Seagen Business Overview
7.5.3 Seagen Antibody-drug Conjugate for Cancer Major Product Offerings
7.5.4 Seagen Antibody-drug Conjugate for Cancer Revenue in Global Market (2017-2022)
7.5.5 Seagen Key News
7.6 Innate Pharma
7.6.1 Innate Pharma Corporate Summary
7.6.2 Innate Pharma Business Overview
7.6.3 Innate Pharma Antibody-drug Conjugate for Cancer Major Product Offerings
7.6.4 Innate Pharma Antibody-drug Conjugate for Cancer Revenue in Global Market (2017-2022)
7.6.5 Innate Pharma Key News
7.7 AstraZeneca
7.7.1 AstraZeneca Corporate Summary
7.7.2 AstraZeneca Business Overview
7.7.3 AstraZeneca Antibody-drug Conjugate for Cancer Major Product Offerings
7.7.4 AstraZeneca Antibody-drug Conjugate for Cancer Revenue in Global Market (2017-2022)
7.7.5 AstraZeneca Key News
7.8 GSK
7.8.1 GSK Corporate Summary
7.8.2 GSK Business Overview
7.8.3 GSK Antibody-drug Conjugate for Cancer Major Product Offerings
7.8.4 GSK Antibody-drug Conjugate for Cancer Revenue in Global Market (2017-2022)
7.8.5 GSK Key News
7.9 Rakuten Medical
7.9.1 Rakuten Medical Corporate Summary
7.9.2 Rakuten Medical Business Overview
7.9.3 Rakuten Medical Antibody-drug Conjugate for Cancer Major Product Offerings
7.9.4 Rakuten Medical Antibody-drug Conjugate for Cancer Revenue in Global Market (2017-2022)
7.9.5 Rakuten Medical Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Antibody-drug Conjugate for Cancer Market Opportunities & Trends in Global Market
Table 2. Antibody-drug Conjugate for Cancer Market Drivers in Global Market
Table 3. Antibody-drug Conjugate for Cancer Market Restraints in Global Market
Table 4. Key Players of Antibody-drug Conjugate for Cancer in Global Market
Table 5. Top Antibody-drug Conjugate for Cancer Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Antibody-drug Conjugate for Cancer Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Antibody-drug Conjugate for Cancer Revenue Share by Companies, 2017-2022
Table 8. Global Companies Antibody-drug Conjugate for Cancer Product Type
Table 9. List of Global Tier 1 Antibody-drug Conjugate for Cancer Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Antibody-drug Conjugate for Cancer Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Antibody-drug Conjugate for Cancer Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Antibody-drug Conjugate for Cancer Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Antibody-drug Conjugate for Cancer Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Antibody-drug Conjugate for Cancer Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Antibody-drug Conjugate for Cancer Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Antibody-drug Conjugate for Cancer Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2023-2028
Table 30. Gilead Sciences Corporate Summary
Table 31. Gilead Sciences Antibody-drug Conjugate for Cancer Product Offerings
Table 32. Gilead Sciences Antibody-drug Conjugate for Cancer Revenue (US$, Mn), (2017-2022)
Table 33. Roche Corporate Summary
Table 34. Roche Antibody-drug Conjugate for Cancer Product Offerings
Table 35. Roche Antibody-drug Conjugate for Cancer Revenue (US$, Mn), (2017-2022)
Table 36. Pfizer Corporate Summary
Table 37. Pfizer Antibody-drug Conjugate for Cancer Product Offerings
Table 38. Pfizer Antibody-drug Conjugate for Cancer Revenue (US$, Mn), (2017-2022)
Table 39. Takeda Corporate Summary
Table 40. Takeda Antibody-drug Conjugate for Cancer Product Offerings
Table 41. Takeda Antibody-drug Conjugate for Cancer Revenue (US$, Mn), (2017-2022)
Table 42. Seagen Corporate Summary
Table 43. Seagen Antibody-drug Conjugate for Cancer Product Offerings
Table 44. Seagen Antibody-drug Conjugate for Cancer Revenue (US$, Mn), (2017-2022)
Table 45. Innate Pharma Corporate Summary
Table 46. Innate Pharma Antibody-drug Conjugate for Cancer Product Offerings
Table 47. Innate Pharma Antibody-drug Conjugate for Cancer Revenue (US$, Mn), (2017-2022)
Table 48. AstraZeneca Corporate Summary
Table 49. AstraZeneca Antibody-drug Conjugate for Cancer Product Offerings
Table 50. AstraZeneca Antibody-drug Conjugate for Cancer Revenue (US$, Mn), (2017-2022)
Table 51. GSK Corporate Summary
Table 52. GSK Antibody-drug Conjugate for Cancer Product Offerings
Table 53. GSK Antibody-drug Conjugate for Cancer Revenue (US$, Mn), (2017-2022)
Table 54. Rakuten Medical Corporate Summary
Table 55. Rakuten Medical Antibody-drug Conjugate for Cancer Product Offerings
Table 56. Rakuten Medical Antibody-drug Conjugate for Cancer Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Antibody-drug Conjugate for Cancer Segment by Type in 2021
Figure 2. Antibody-drug Conjugate for Cancer Segment by Application in 2021
Figure 3. Global Antibody-drug Conjugate for Cancer Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Antibody-drug Conjugate for Cancer Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Antibody-drug Conjugate for Cancer Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Antibody-drug Conjugate for Cancer Revenue in 2021
Figure 8. By Type - Global Antibody-drug Conjugate for Cancer Revenue Market Share, 2017-2028
Figure 9. By Application - Global Antibody-drug Conjugate for Cancer Revenue Market Share, 2017-2028
Figure 10. By Region - Global Antibody-drug Conjugate for Cancer Revenue Market Share, 2017-2028
Figure 11. By Country - North America Antibody-drug Conjugate for Cancer Revenue Market Share, 2017-2028
Figure 12. US Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Antibody-drug Conjugate for Cancer Revenue Market Share, 2017-2028
Figure 16. Germany Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2028
Figure 17. France Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Antibody-drug Conjugate for Cancer Revenue Market Share, 2017-2028
Figure 24. China Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2028
Figure 28. India Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Antibody-drug Conjugate for Cancer Revenue Market Share, 2017-2028
Figure 30. Brazil Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Antibody-drug Conjugate for Cancer Revenue Market Share, 2017-2028
Figure 33. Turkey Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Antibody-drug Conjugate for Cancer Revenue, (US$, Mn), 2017-2028
Figure 37. Gilead Sciences Antibody-drug Conjugate for Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Roche Antibody-drug Conjugate for Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Pfizer Antibody-drug Conjugate for Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Takeda Antibody-drug Conjugate for Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Seagen Antibody-drug Conjugate for Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Innate Pharma Antibody-drug Conjugate for Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. AstraZeneca Antibody-drug Conjugate for Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. GSK Antibody-drug Conjugate for Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Rakuten Medical Antibody-drug Conjugate for Cancer Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Industry Market Size
